/* FIMAVYN PHASE 2B — accessibility safeguards without visual redesign. */
.skip-link{position:fixed;left:16px;top:16px;z-index:10000;padding:12px 16px;border-radius:8px;background:#fff;color:#073b2d;font-weight:800;box-shadow:0 4px 18px rgba(0,0,0,.25);transform:translateY(-160%);transition:transform .15s ease}
.skip-link:focus{transform:translateY(0)}
:where(a,button,summary,[tabindex]):focus-visible{outline:3px solid #f0c64d;outline-offset:4px}
#main-content:focus{outline:none}
picture{display:contents}
@media (prefers-reduced-motion:reduce){html{scroll-behavior:auto!important}*,*::before,*::after{animation-duration:.01ms!important;animation-iteration-count:1!important;transition-duration:.01ms!important;scroll-behavior:auto!important}}
@media (forced-colors:active){:where(a,button,summary,[tabindex]):focus-visible{outline:3px solid CanvasText}}